High-dose amikacin for achieving serum target levels in critically ill elderly patients
- PMID: 29483780
- PMCID: PMC5815475
- DOI: 10.2147/IDR.S150839
High-dose amikacin for achieving serum target levels in critically ill elderly patients
Abstract
Introduction: To achieve target concentrations, the application of higher-than-standard doses of amikacin is proposed for the treatment of sepsis due to an increase in volume of distribution and clearance, but little data are available on aminoglycoside administration in critically ill elderly patients.
Patients and methods: Forty critically ill elderly patients (aged over 65 years) who required amikacin therapy due to severe documented, or suspected gram-negative infections, were randomly assigned to two treatment groups. Group A (20 patients) received 15 mg/kg amikacin and Group B (20 patients) received 25 mg/kg amikacin per day as a single daily dose. All the patients were monitored for renal damage by the daily monitoring of serum creatinine. The amikacin peak (Cmax) and trough (Cmin) serum concentrations were measured on Days 3 and 7 postadministration.
Results: Data from 18 patients in Group A and 15 patients in Group B were finally analyzed. On Day 3, the amikacin mean Cmax levels in the standard and high-dose treatment groups were 30.4±11 and 52.3±16.1 µg/mL (P<0.001), and the Cmin levels were 3.2±2.1 and 5.2±2.8 µg/mL, respectively (P=0.035). On Day 7, the Cmax levels in the standard and high-dose groups were 33±7.3 and 60.0±17.6 µg/mL (P=0.001), and the Cmin levels were 3.2±2.9 and 9.3±5.6 µg/mL, respectively (P=0.002). In only six (40%) of the patients in the high-dose groups and none of the patients in the standard-dose group, amikacin Cmax reached the target levels (>64 µg/mL), whereas the amikacin mean Cmin levels in the high-dose group were above the threshold of toxicity (5 µg/mL).
Conclusion: Our results suggest that the optimum dose of amikacin should be determined for elderly critically ill patients. It seems that higher-than-standard doses of amikacin with more extended intervals might be more appropriate than standard once-daily dosing in the elderly critically ill patients.
Keywords: amikacin; critical illness; elderly; high-dose; pharmacokinetics; therapeutic drug monitoring.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Similar articles
-
Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.Eur J Hosp Pharm. 2022 Mar;29(e1):e67-e71. doi: 10.1136/ejhpharm-2021-002986. Epub 2021 Sep 29. Eur J Hosp Pharm. 2022. PMID: 34588225 Free PMC article.
-
Amikacin therapeutic drug monitoring: Evaluation of therapy performance and analytical techniques in a developing country setting.Clin Biochem. 2025 Mar;136:110874. doi: 10.1016/j.clinbiochem.2025.110874. Epub 2025 Jan 4. Clin Biochem. 2025. PMID: 39761849
-
Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.Acta Med Iran. 2014;52(9):703-9. Acta Med Iran. 2014. PMID: 25325208 Clinical Trial.
-
Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation.Crit Care. 2018 Aug 19;22(1):199. doi: 10.1186/s13054-018-2122-x. Crit Care. 2018. PMID: 30121083 Free PMC article.
-
Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):285-91. Eur Rev Med Pharmacol Sci. 2013. PMID: 23426530 Clinical Trial.
Cited by
-
Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis.Adv Pharm Bull. 2020 Jan;10(1):114-118. doi: 10.15171/apb.2020.014. Epub 2019 Dec 11. Adv Pharm Bull. 2020. PMID: 32002369 Free PMC article.
-
MarR-Dependent Transcriptional Regulation of mmpSL5 Induces Ethionamide Resistance in Mycobacterium abscessus.Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0135022. doi: 10.1128/aac.01350-22. Epub 2023 Mar 29. Antimicrob Agents Chemother. 2023. PMID: 36988462 Free PMC article.
-
Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin.Pharmaceutics. 2021 Feb 15;13(2):264. doi: 10.3390/pharmaceutics13020264. Pharmaceutics. 2021. PMID: 33672057 Free PMC article.
-
Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients.Antibiotics (Basel). 2023 Feb 11;12(2):373. doi: 10.3390/antibiotics12020373. Antibiotics (Basel). 2023. PMID: 36830283 Free PMC article.
-
Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations.Eur J Hosp Pharm. 2023 Jul;30(4):189-195. doi: 10.1136/ejhpharm-2022-003421. Epub 2022 Nov 7. Eur J Hosp Pharm. 2023. PMID: 36344247 Free PMC article.
References
-
- Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother. 2009;63(2):246–251. - PubMed
-
- Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008;32(4):294–301. - PubMed
-
- Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21(2):172–173. - PubMed
-
- Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–99. - PubMed
-
- Aminoglycosides: EUCAST clinical MIC breakpoints. Available from: http://www.eucast.org/clinical_breakpoints/
LinkOut - more resources
Full Text Sources
Other Literature Sources